COYA Coya Therapeutics, Inc.
USHealthcareAs of 2026-08-24
Why COYA matters now
Coya Therapeutics, Inc. (COYA) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.96 with +1.85% on the session and $116.3M in market capitalization; recent performance reads 1-month +7.66% and YTD -15.17%.
The latest financial table shown here is Q1 2026, with revenue of $251.1K, net income of $-7.2M, and EPS of $-0.32. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -15.8%.
The latest indexable market news headline is "Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $12.00; recent insider activity includes Pavao Mark H filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.68
P/S
11.28
EV/EBITDA
-1.84
DCF Value
$4.83
FCF Yield
-15.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.8%
Operating Margin
-277.0%
Net Margin
-266.1%
ROE
-57.3%
ROA
-39.7%
ROIC
-44.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $251.1K | $-7.2M | $-0.32 |
| Q4 2025 | $4.0M | $-5.7M | $-0.34 |
| FY 2025 | $7.9M | $-21.2M | $-1.27 |
| Q3 2025 | $3.6M | $-2.1M | $-0.13 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$12.00
Target (Median)
$12.00
Target Range
$12.00 - $12.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.62
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.